Skip to content

Oral Health Status in Patients With Cirrhosis and Effect of Dental Treatment on MELD Score of Cirrhosis Patients

Evaluation of Oral Health Status in Patients With Cirrhosis and Effect of Dental Treatment on MELD Score of Cirrhosis Patients

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04399512
Enrollment
110
Registered
2020-05-22
Start date
2020-01-01
Completion date
2021-06-30
Last updated
2020-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver Cirrhosis, Periapical Lesions

Keywords

Apical periodontitis, liver disease, root canal treatment

Brief summary

It has been found that there is an association between prevalence of odontogenic infection and systemic diseases.Cirrhosis has also been associated with poor oral health status.Treating those patients accordingly can help in reducing the source of infection to some extent and may be associated with reduction in mortality.

Detailed description

Patients will be selected according to inclusion and exclusion criteria.Written informed consent will be taken from each participant after being informed about study .There will be two groups1) cirrhosis patients 2)normal healthy patients.Prevalence of apical periodontitis will be measured in both groups by intraoral examination,digital panoramic radiography.. MELD score will be recorded in cirrhosis patients at this stage.Non surgical root canal treatment will be performed in teeth with apical periodontitis. Periapical healing will be checked with the help of PAI Score given by Orstavik. In Cirrhosis patients MELD Score will be measured before and after treatment.

Interventions

Nonsurgical root canal treatment will be given

Sponsors

Postgraduate Institute of Dental Sciences Rohtak
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Intervention model description

Cross-sectional and Interventional study

Eligibility

Sex/Gender
ALL
Age
35 Years to 55 Years
Healthy volunteers
Yes

Inclusion criteria

(cirrhosis patients) 1. Known patient of cirrhosis(Diagnosis of cirrhosis is based on blood testing, medical imaging, and liver biopsy.) with mature permanent teeth . 2. Age35-55 years 3. \> or equal to 8 natural teeth(excluding 3rd molars); 4. I.N.R \< 3.5 \-

Exclusion criteria

(Cirrhosis patients) 1. Patient having systemic disorders other than hepatic disease(e.g. HIV, osteoporosis,diabetes,cardiovascular disease) 2. Pregnancy 3. Use of systemic and topical antibiotic treatment within 3 months prior to the start of the study. The eligibility criteria of the control group were the same for the cirrhosis group, except for the presence of liver disease. Cirrhosis patients were matched with controls according to sex, age (± 3 years old) and current smoking status and alcohol satus (yes/no). \-

Design outcomes

Primary

MeasureTime frameDescription
prevalence of apical periodontitis in patients with cirrhosis and healthy patients.Baseline to 12 monthsperiapical index score will be assigned to intraoral periapical radiograph of teeth showing periapical radiolucency in orthopantomogram of each patient .PAI score 3,4,5 will be diagnosed with apical periodontitis . Score Description 1. Normal periapical structure 2. Small changes in bone structure 3. Changes in bone structure with some mineral loss 4. Periodontitis with well-defined radiolucent area 5. Severe periodontitis with exacerbating features

Secondary

MeasureTime frameDescription
association of prevalence of marginal and apical periodontitis with mortality measured by MELD score in cirrhosis patientsBaseline to 12 monthsModel for end stage liver disease score of all cirrhotic patients will be calculated using serum bilirubin, serum creatinine, and International Normalized Ratio (INR) by the formula 9.57 × loge (creatinine) + 3.78 × loge (total bilirubin) + 11.2 × loge (INR) + 6.43.
Clinical and radiographic successBaseline to 12 monthsClinical success will be assessed by absence of clinical signs and symptoms and radiographically PAI score 1 ,2 will be considered as healed.

Countries

India

Contacts

Primary ContactSwati Sharma
sharma.swati18787@gmail.com8199925698

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026